The Danish Health Board noted that the European Medicines Agency (EMA) “concluded that there was a possible link between rare but severe blood clots” and the J&J vaccine.
Both the World Health Organization (WHO) and the EEA have approved J&J vaccines and state that their benefits outweigh the potential risks.
However, Danish health officials said the country could do without the J&J vaccine in the event of a favorable epidemiological situation in the country, and would only be vaccinated with Pfizer / BioNTech and Moderna vaccines.
“The Danish Board of Health has concluded that the benefits of using Johnson & Johnson’s COVID-19 vaccine do not outweigh the risks of possible side effects … for those receiving the vaccine,” the agency said in a statement.
“Therefore, the Danish Board of Health will continue the Danish mass vaccination program against COVID-19 without Johnson & Johnson’s COVID-19 vaccine,” he added.
The Board of Health noted that the epidemic in Denmark is currently under control and vaccinations are being carried out using other vaccines.
However, the board acknowledged that the decision would slow down the vaccination campaign.
J&J is reported to be removed from the program after receiving information about several cases of unusual blood clots with a decrease in platelets among people vaccinated with J&J in the United States.
The EVA said on April 20 that unusual blood clots should be described as a “very rare” side effect of the J&J coronavirus vaccine, but stressed that the benefits of these vaccines still outweigh the risks.
In April, the United States suspended the use of the J&J vaccine, linked to rare cases of thrombosis.
J&J had postponed the distribution of its single-dose vaccine in Europe and decided to wait for the EVA to publish the results of its study, but said it had “strong confidence” in its vaccine.
In April, Denmark announced that it would no longer use AstraZeneca’s pandemic coronavirus vaccine, following rare but serious blood clots in people who had been vaccinated.
Despite recommendations from the WHO and the EEA to continue vaccination with the vaccine, “the Danish vaccination campaign will continue without the AstraZeneca vaccine,” said Sioren Brostriom, director of the Danish Health Board.
Denmark was the first country in Europe to stop using AstraZeneca.
Dozens followed the Danish example, but all but a few resumed vaccination with the vaccine, with the EVA emphasizing the benefits of the vaccine and stating that it considered it “safe and effective”.
Denmark has said it could reassess the benefits of using both of these vaccines if the situation changes.
“New information may become available or the situation in Denmark may change, for example in terms of infectious pressure, disease burden, epidemic control or the availability of other vaccines,” the Health Board said.
Of the 5.8 million. 11.5 percent of the Danish population are fully vaccinated and 23.4 percent. received the first dose of vaccine.
There are currently four COVID-19 approved vaccines in the EU: Pfizer / BioNTech, Moderna, AstraZeneca and Johnson & Johnson. The latter two are for the elderly in most European countries.